![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/09/shutterstock_1077768686.jpg)
ESC 2024: GLP-1RAs show lower CV risk in 32,883-strong meta-analysis
Results have been presented at the European Society of Cardiology (ESC) Congress 2024 of a meta-analysis that studied the cardiovascular outcomes of glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with obesity without diabetes mellitus. The …